(70 days)
The SPOTCHEM II LDH test is intended to measure the activity of the enzyme lactate dehydrogenase in serum, plasma, and whole blood. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction, and tumors of the lung or kidneys.
Not Found
The provided text is a 510(k) substantial equivalence letter from the FDA for a medical device (Arkray SPOTCHEM II LDH test). It does not contain any information about acceptance criteria, device performance details, specifics of a study, sample sizes, expert qualifications, or ground truth establishment relevant to the listed questions.
This document is a regulatory approval letter, not a scientific study report or a summary of performance data. Therefore, I cannot extract the requested information from the given text.
To answer your questions, I would need a different type of document, such as:
- A clinical study report
- A performance evaluation report
- A detailed 510(k) submission document (beyond just the decision letter)
- A scientific publication describing the device's validation.
§ 862.1440 Lactate dehydrogenase test system.
(a)
Identification. A lactate dehydrogenase test system is a device intended to measure the activity of the enzyme lactate dehydrogenase in serum. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction, and tumors of the lung or kidneys.(b)
Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.